Structure Encountered
Bambusa Therapeutics
Develops bispecific antibodies for Type 2 inflammatory and immunological diseases
Bambusa's BBT002 (IL-4Rα×IL-5) shows 8-week PD effects from a single dose with 29.4-day half-life at ATS 2026. First CRSwNP patient dosed in Phase 1b/2a; COPD topline lands by year-end.
SIGNAL·Phase 1 clinical data presentation (ATS 2026) + Phase 1b/2a first patient dosing·Phase 1 single ascending dose data in healthy volunteers: biomarker effects (pSTAT6 inhibition, TARC reduction, eosinophil depletion) lasting at least 8 weeks from a single dose; half-life of ~29.4 days. First patient dosed Phase 1b/2a CRSwNP trial. COPD Phase 1b/2a topline expected year-end 2026; CRSwNP topline expected H1 2027.·SCORE 84·19 MAY 2026 · 12:47 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / BAMBUSA THERAPEUTICS
/ Boston, Massachusetts, United States
CAPT. / 19.05.26 12:47:05Z
SIGNAL / 84 / 100
Image relayed by The Biotech Voyager during pass over structure Bambusa Therapeutics. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
Bambusa Therapeutics
Coordinates
Boston, Massachusetts, United States
Stage
Phase 1
Type
Therapeutics
Modalities
antibody · bispecific
Therapeutic area
Immunology · Dermatology · Respiratory · Autoimmune
002Signature Detected
EVENT DETECTED
Event type
Phase 1 clinical data presentation (ATS 2026) + Phase 1b/2a first patient dosing
Magnitude
Phase 1 single ascending dose data in healthy volunteers: biomarker effects (pSTAT6 inhibition, TARC reduction, eosinophil depletion) lasting at least 8 weeks from a single dose; half-life of ~29.4 days. First patient dosed Phase 1b/2a CRSwNP trial. COPD Phase 1b/2a topline expected year-end 2026; CRSwNP topline expected H1 2027.
Lead
Bambusa Therapeutics (sponsor)
Participating
None disclosed
Use of capital
N/A (no financing event); pipeline funded by prior $15M seed (Sept 2024, BVF + Dawn/KKR co-led), $90M Series A (Feb 2025, RA Capital-led) and Series A-2 (Nov 2025, oversubscribed at step-up valuation).
003Architecture
PLATFORM PROFILE
Target class
IL-4Rα + IL-5 (bispecific antibody combining type 2 cytokine receptor blockade with eosinophil-targeting cytokine inhibition)
Differentiator
29.4 day half-life on a single SC dose. That's the same range as BBT001 (33-day) and meaningfully longer than most marketed Type 2 biologics in respiratory. Pairing IL-4Rα (the Dupixent target) with IL-5 (the Nucala target) on one molecule means Bambusa is testing whether you can do Dupixent + Nucala in one shot, every couple months, for COPD and CRSwNP patients who currently need both pathways suppressed. PD biomarkers held for 8 weeks after a single dose.
Lead asset
BBT002 (bispecific antibody, IL-4Rα × IL-5, half-life extended, Phase 1 with Phase 1b/2a in COPD and CRSwNP)
Pipeline depth
Two clinical bispecifics: BBT001 (IL-4Rα×IL-31, Phase 1/1b/2a for moderate-to-severe AD, enrollment complete April 2026, topline mid-2026) and BBT002 (Phase 1 SAD data ATS 2026, Phase 1b/2a in COPD topline YE2026 and CRSwNP topline H1 2027). Preclinical: BBT003 (IBD), BBT004 (rheumatology). Up to ten clinical readouts anticipated in 2026.
004Voyager Assessment
MACHINE-GENERATED
Bambusa is now publicly running both clinical bispecifics. BBT001 reads out mid-2026 in atopic dermatitis. BBT002 has clean Phase 1 biomarker data in hand and is now in two Phase 1b/2a trials, one for COPD with topline by year-end 2026 and one for CRSwNP with topline in H1 2027. The 29.4 day half-life and 8-week PD effect from a single dose set up quarterly dosing as the differentiator versus Dupixent and Nucala. Watch the COPD readout. That's where this either becomes a pharma target or has to keep building.
005Adjacent Structures
FRONTIER MAP
Sanofi/Regeneron· Dupixent IL-4Rα incumbentGSK· Nucala IL-5 incumbentApogee Therapeutics· extended half-life IL-13 in ADWindward Bio· long-acting respiratory bispecificsTriveni Bio· KLK5/7×IL-13 AD bispecificPoplar Therapeutics· anti-IgE atopic diseaseEarendil Labs· biparatopic anti-TSLPProteologix· AD bispecific acquired by JNJ
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.